Is SYRE or MLYS more profitable?

Mineralys Therapeutics' return on equity of -27.92% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Mineralys Therapeutics N/A -27.92% -26.98%

Does the media prefer SYRE or MLYS?

In the previous week, Spyre Therapeutics had 4 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 7 mentions for Spyre Therapeutics and 3 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.10 beat Spyre Therapeutics' score of 0.54 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MLYS or PRAX more profitable?

Mineralys Therapeutics' return on equity of -27.92% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Mineralys Therapeutics N/A -27.92% -26.98% Praxis Precision Medicines N/A -43.02% -40.22%

Does the media prefer MLYS or PRAX?

In the previous week, Praxis Precision Medicines had 6 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 9 mentions for Praxis Precision Medicines and 3 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.10 beat Praxis Precision Medicines' score of 0.82 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MLYS or TGTX?

In the previous week, Mineralys Therapeutics and Mineralys Therapeutics both had 3 articles in the media. TG Therapeutics' average media sentiment score of 1.14 beat Mineralys Therapeutics' score of 1.10 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, APGE or MLYS?

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apogee Therapeutics N/A N/A -$255.84M -$4.33 N/A Mineralys Therapeutics N/A N/A -$154.65M -$2.05 N/A

Is APGE or MLYS more profitable?

Mineralys Therapeutics' return on equity of -27.92% beat Apogee Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apogee Therapeutics N/A -32.64% -31.25% Mineralys Therapeutics N/A -27.92% -26.98%

Does the media prefer APGE or MLYS?

In the previous week, Apogee Therapeutics had 41 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 44 mentions for Apogee Therapeutics and 3 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.10 beat Apogee Therapeutics' score of 0.18 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 11 Very Positive mention(s) 7 Positive mention(s) 16 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ABVX or MLYS?

Abivax is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Mineralys Therapeutics N/A N/A -$154.65M -$2.05 N/A

Is ABVX or MLYS more profitable?

Mineralys Therapeutics' return on equity of -27.92% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Mineralys Therapeutics N/A -27.92% -26.98%

Does the media prefer ABVX or MLYS?

In the previous week, Abivax and Abivax both had 3 articles in the media. Mineralys Therapeutics' average media sentiment score of 1.10 beat Abivax's score of 0.84 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Mineralys Therapeutics (MLYS) Competitors

$26.11 -0.23 (-0.89%)

As of 10:51 AM Eastern

Compare

MLYS vs. SYRE, PRAX, TGTX, APGE, and ABVX

Should you buy Mineralys Therapeutics stock or one of its competitors? MarketBeat compares Mineralys Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mineralys Therapeutics include Spyre Therapeutics (SYRE), Praxis Precision Medicines (PRAX), TG Therapeutics (TGTX), Apogee Therapeutics (APGE), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

How does Mineralys Therapeutics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Mineralys Therapeutics has lower revenue, but higher earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,641.07	-$155.20M	-$2.08	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Spyre Therapeutics has a beta of 3.05, indicating that its stock price is 205% more volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

In the previous week, Spyre Therapeutics had 4 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 7 mentions for Spyre Therapeutics and 3 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.10 beat Spyre Therapeutics' score of 0.54 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mineralys Therapeutics' return on equity of -27.92% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

Spyre Therapeutics presently has a consensus price target of $95.83, suggesting a potential upside of 8.21%. Mineralys Therapeutics has a consensus price target of $49.33, suggesting a potential upside of 89.70%. Given Mineralys Therapeutics' higher probable upside, analysts plainly believe Mineralys Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Mineralys Therapeutics beats Spyre Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Praxis Precision Medicines?

Mineralys Therapeutics (NASDAQ:MLYS) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Mineralys Therapeutics currently has a consensus target price of $49.33, indicating a potential upside of 89.70%. Praxis Precision Medicines has a consensus target price of $566.21, indicating a potential upside of 71.62%. Given Mineralys Therapeutics' higher probable upside, research analysts clearly believe Mineralys Therapeutics is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95

Mineralys Therapeutics has higher earnings, but lower revenue than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Praxis Precision Medicines	$8.55M	1,075.81	-$303.27M	-$13.37	N/A

In the previous week, Praxis Precision Medicines had 6 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 9 mentions for Praxis Precision Medicines and 3 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.10 beat Praxis Precision Medicines' score of 0.82 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Mineralys Therapeutics' return on equity of -27.92% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Mineralys Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, suggesting that its share price is 171% more volatile than the broader market.

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Mineralys Therapeutics beats Praxis Precision Medicines on 9 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to TG Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

In the previous week, Mineralys Therapeutics and Mineralys Therapeutics both had 3 articles in the media. TG Therapeutics' average media sentiment score of 1.14 beat Mineralys Therapeutics' score of 1.10 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 65.95% compared to Mineralys Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
TG Therapeutics	65.95%	88.73%	43.44%

Mineralys Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

Mineralys Therapeutics currently has a consensus price target of $49.33, indicating a potential upside of 89.70%. TG Therapeutics has a consensus price target of $58.60, indicating a potential upside of 8.44%. Given Mineralys Therapeutics' higher possible upside, equities analysts clearly believe Mineralys Therapeutics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by company insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

TG Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
TG Therapeutics	$700.35M	11.81	$447.18M	$2.86	18.90

Summary

TG Therapeutics beats Mineralys Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

Apogee Therapeutics currently has a consensus target price of $121.25, indicating a potential downside of 8.61%. Mineralys Therapeutics has a consensus target price of $49.33, indicating a potential upside of 89.70%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Apogee Therapeutics had 41 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 44 mentions for Apogee Therapeutics and 3 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.10 beat Apogee Therapeutics' score of 0.18 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	11 Very Positive mention(s)	7 Positive mention(s)	16 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mineralys Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mineralys Therapeutics' return on equity of -27.92% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

Apogee Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

Summary

Mineralys Therapeutics beats Apogee Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Mineralys Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Mineralys Therapeutics (NASDAQ:MLYS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Mineralys Therapeutics' return on equity of -27.92% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Mineralys Therapeutics	N/A	-27.92%	-26.98%

Abivax has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

Abivax is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A

Abivax currently has a consensus target price of $130.08, indicating a potential upside of 32.84%. Mineralys Therapeutics has a consensus target price of $49.33, indicating a potential upside of 89.70%. Given Mineralys Therapeutics' higher probable upside, analysts clearly believe Mineralys Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Abivax and Abivax both had 3 articles in the media. Mineralys Therapeutics' average media sentiment score of 1.10 beat Abivax's score of 0.84 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mineralys Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.9% of Abivax shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Mineralys Therapeutics beats Abivax on 9 of the 12 factors compared between the two stocks.

Get Mineralys Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLYS vs. The Competition

Export

Metric	Mineralys Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.15B	$3.52B	$6.61B	$12.27B
Dividend Yield	N/A	2.27%	2.68%	5.90%
P/E Ratio	-12.74	21.12	25.76	23.98
Price / Sales	N/A	331.25	550.19	97.97
Price / Cash	N/A	134.91	46.33	53.91
Price / Book	3.18	8.04	10.57	6.32
Net Income	-$154.65M	$23.91M	$3.57B	$337.22M
7 Day Performance	5.59%	1.36%	0.76%	-1.25%
1 Month Performance	-13.28%	0.77%	0.19%	-0.63%
1 Year Performance	85.76%	56.92%	30.79%	27.95%

Mineralys Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLYS Mineralys Therapeutics	4.5353 of 5 stars	$26.11 -0.9%	$49.33 +89.0%	+85.0%	$2.16B	N/A	N/A	28	Positive News
SYRE Spyre Therapeutics	1.8354 of 5 stars	$99.14 -1.2%	$95.83 -3.3%	+464.1%	$8.59B	$890K	N/A	73	Analyst Forecast Insider Trade Gap Down
PRAX Praxis Precision Medicines	3.3466 of 5 stars	$305.30 +0.6%	$566.21 +85.5%	+656.7%	$8.49B	$8.55M	N/A	110	Gap Up
TGTX TG Therapeutics	3.0123 of 5 stars	$54.14 -0.5%	$58.60 +8.2%	+43.9%	$8.32B	$700.35M	19.00	290	Positive News
APGE Apogee Therapeutics	1.42 of 5 stars	$132.86 +0.2%	$119.67 -9.9%	+208.6%	$8.23B	N/A	N/A	91	Analyst Downgrade Insider Trade Options Volume High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLYS) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. SYRE, PRAX, TGTX, APGE, and ABVX

How does Mineralys Therapeutics compare to Spyre Therapeutics?

Summary

How does Mineralys Therapeutics compare to Praxis Precision Medicines?

Summary

How does Mineralys Therapeutics compare to TG Therapeutics?

Summary

How does Mineralys Therapeutics compare to Apogee Therapeutics?

Summary

How does Mineralys Therapeutics compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mineralys Therapeutics (MLYS) Competitors

MLYS vs. SYRE, PRAX, TGTX, APGE, and ABVX

How does Mineralys Therapeutics compare to Spyre Therapeutics?

Which has preferable valuation & earnings, SYRE or MLYS?

Do insiders and institutionals hold more shares of SYRE or MLYS?

Which has more risk & volatility, SYRE or MLYS?

Does the media prefer SYRE or MLYS?

Is SYRE or MLYS more profitable?

Do analysts recommend SYRE or MLYS?

Summary

How does Mineralys Therapeutics compare to Praxis Precision Medicines?

Do analysts rate MLYS or PRAX?

Which has stronger valuation and earnings, MLYS or PRAX?

Does the media prefer MLYS or PRAX?

Is MLYS or PRAX more profitable?

Which has more risk & volatility, MLYS or PRAX?

Do insiders & institutionals believe in MLYS or PRAX?

Summary

How does Mineralys Therapeutics compare to TG Therapeutics?

Does the media refer more to MLYS or TGTX?

Is MLYS or TGTX more profitable?

Which has more volatility & risk, MLYS or TGTX?

Do analysts rate MLYS or TGTX?

Do insiders and institutionals have more ownership in MLYS or TGTX?

Which has preferable valuation & earnings, MLYS or TGTX?

Summary

How does Mineralys Therapeutics compare to Apogee Therapeutics?

Do analysts rate APGE or MLYS?

Do insiders & institutionals have more ownership in APGE or MLYS?

Does the media prefer APGE or MLYS?

Is APGE or MLYS more profitable?

Which has more volatility and risk, APGE or MLYS?

Which has higher valuation & earnings, APGE or MLYS?

Summary

How does Mineralys Therapeutics compare to Abivax?

Is ABVX or MLYS more profitable?

Which has more risk and volatility, ABVX or MLYS?

Which has preferable earnings & valuation, ABVX or MLYS?

Do analysts prefer ABVX or MLYS?

Does the media prefer ABVX or MLYS?

Do institutionals and insiders believe in ABVX or MLYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS vs. The Competition

Mineralys Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools